Canada Markets closed
  • S&P/TSX

    20,383.77
    +39.70 (+0.20%)
     
  • S&P 500

    4,026.12
    -1.14 (-0.03%)
     
  • DOW

    34,347.03
    +152.97 (+0.45%)
     
  • CAD/USD

    0.7476
    -0.0024 (-0.3214%)
     
  • CRUDE OIL

    76.28
    -1.66 (-2.13%)
     
  • BTC-CAD

    22,227.11
    +38.36 (+0.17%)
     
  • CMC Crypto 200

    386.97
    +4.32 (+1.13%)
     
  • GOLD FUTURES

    1,754.00
    +8.40 (+0.48%)
     
  • RUSSELL 2000

    1,869.19
    +5.67 (+0.30%)
     
  • 10-Yr Bond

    3.6910
    -0.0150 (-0.40%)
     
  • NASDAQ

    11,226.36
    -58.96 (-0.52%)
     
  • VOLATILITY

    20.50
    +0.08 (+0.39%)
     
  • FTSE

    7,486.67
    +20.07 (+0.27%)
     
  • NIKKEI 225

    28,283.03
    -100.06 (-0.35%)
     
  • CAD/EUR

    0.7186
    -0.0015 (-0.21%)
     

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit

COMPASS Pathways
COMPASS Pathways

LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at Jefferies Innovation in Mental Health Summit at 8:30am ET on 22 September 2022.

A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the COMPASS website. Each replay of the webcast will be accessible for 30 days following each event. For more information, please visit ir.compasspathways.com

About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted, and our topline data showed a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also running phase II clinical trials of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing. www.compasspathways.com

Availability of other information about COMPASS Pathways
Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Enquiries
Media: Amy Lawrence, amy@compasspathways.com, +44 7813 777 919
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324